This is to inform you that pursuant to Regulation 30 & Regulation 33 of Securities Exchange Board of India (Listing Obligation and Disclosure requirement) Regulation 2015 'Listing regulation' ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pentokey Organy (India) Limited, a pharma and pesticides trading company, announced its Q3 FY26 (Dec 2025) results. Revenue from operations for the quarter stood at negative Rs 209.14 lakh, indicating a reversal or credit note during the quarter, compared to Rs 98.33 lakh in the previous quarter. Despite this, the company reported a profit of Rs 33.41 lakh for the nine months ended Dec 2025, up significantly from Rs 18.90 lakh in the same period last year. The quarter alone swung to a loss of Rs 29.30 lakh versus a profit of Rs 14.23 lakh in Q2 FY26, dragging Q3 EPS to negative Rs 0.47. The statutory auditors (Verma Mehta & Associates) issued an unmodified review report. The company also disclosed an outstanding income tax demand of Rs 171.58 lakh for AY 2015-16, which is under appeal.
The sharp negative revenue in Q3 is a red flag and suggests possible product returns, pricing reversals, or a one-time accounting adjustment, which may concern short-term investors. However, the nine-month performance remains strongly profitable with healthy growth. Shareholders should watch for clarity on the Q3 revenue reversal and the pending tax dispute of Rs 171.58 lakh.